Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Biohaven charts comeback path after FDA blow, placing bets on obesity

Biohaven charts comeback path after FDA blow, placing bets on obesity

  • February 20, 2026

After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it zeroes in on obesity. 

Leave A Comment

Fields (*) Mark are Required